(1) belongs to a new class of antine'oplastic agents and has shown dose-dependent activity in methytnitrosourea (MHU)-induced rat mammary carcinoma.
The cylotoxio effect of these compounds on tumor celts has been related to the deficiency of 1-:O-alky[-cleavage enzyme. Therefore it was intented to develop ana[ogous compounds which are better substrates to this enzyme to facilitate detoxifisatien in normal cells.
The following compounds have been tested (treatment 5x/week for 5 weeks, p.o.)
in SD-rats bearing methylnitrosourea (MNU)-induced mammary carcinoma in comparison to (1).
2)1 -O-OetadecyIpropanediol-(1.3)-phoshochoIine
3)1 -O-Hexadecylpr opanedio [-(1.3) 
Compounds (C) 1,2,3 and 5 were given in three doses (115,77,51 p, mot/k9 bw), C 3 in two doses (115,77 p, mol/k9 bw) and C 6 in one dose (115p, mol/kg bw).
Therapeutic effect was evaluated by measuring tumor volumes of treated and control animals (T/C "4) and tumor numbers per rat (TH), toxicity by ~4mortality (~M) and median body weight differenc e ('~8WD).
Results: C 2, 3 and 5 which were shown to be better substrates for the 1-O-alky|-cteavage enzyme compared to 1 exhibited no therapeutic effect, only C 3 showed a markedly decreased toxieity. C 4 given in the highest dose (115 p, mot/k 9) had a comparable therapeutic effect as 1 given in a dose of 77 p, mo[/kg (T/C'~ 44 vs 46 ).
The toxicity was considerable lower than the toxicity of 1 in the highest dose.
C 6 which is not a O-alkyl-ether and therefor no substrato for the detoxifying enzyme showed the highest ant[neoplastic activity in our model; following data were obtained, comparing equimo[ar doses of 6 and 1 : T/C"4 1.1 and 23, TN 1(0-1) and 6(5-9), gBWD -6.6 and -3. New York, 277, 1983) . With respect to the cytotoxic properties, we observed in our studies that incubation of Raji cells with different (alkyl)-lysophospholipids of almost identical haemolytic activity resulted in a very differentiated toxicity against these cells. This result is not understood on a molecular level. Therefore, we performed experiments to explore the mechanisms which lead to the differentiated toxicity of (alkyl)-lysophospholipids with very similar properties.
Methods: Phospholipid-metabolizing enzymes were studied in vitro and in vivo by using spectrophotometric tests and incubations with radiolabeiled (alkyl)-lysophospholipids for the analysis of the metabolic fate of these molecules in the cell (C. Unger et al., Cancer Res. 45, 616, 1985 Aim of research: It was the aim of this study to look for antineoplastic agents with a selective toxicity against tumour cells. This goal may be achieved with the help of phospholipid-metabolizing enzymes. As described in the literature for the 1-O-alkyl cleavage enzyme (J.F. Soodsma et al., Cancer Res. 30, 309, 1970) , there are quantitative differences in the enzyme equipment between tumour tissue and normal cells. "Tailor-made" (alkyl)-lysophospholipids with substrate properties for the cleavage enzyme are expected to be less toxic to normal cells than the most studied 1-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, which is no substrate for this enzyme (C. Unger et al., Cancer Res. 45, 616, 1985) .
Methods: Cytotoxic effects of the new agents were studied against different leukaemic cells, in comparison to a fibroblastic cell line, by inhibition of (3H)thymidine incorporation into DNA, and the trypan blue dye exclusion test.
Results: The compound inhibited the in vitro incorporation of tritiated thymidine into HL 60, Raji and K 562 human leukaemic cell lines. This activity was well correlated with trypan blue dye exclusion. Complete cell destruction was achieved with 2.5 ~g/ml (HL 60) , 12 ~g/ml (Raji) and 25 ~g/ml (K 562) after an incubation time of about 72 hrs = no toxic effects on fibroblasts up to 40 pg/ml. In addition, the first results indicate that 1-hexacecyl-propandiol-(l.2)-phosphocholine is an active compound in the treatment of nitrosourea-induced mammary carcinomas of the rat. Conclusions: From our results we learnt that l-hexadecylpropandiol-(1.2)-phosphocholine is a powerful new antineoplastic agent with remarkable differences in the toxic concentrations between tumour and normal cells. 
